Application of quantitative models from population biology and evolutionary game theory to tumor therapeutic strategies

Molecular Cancer Therapeutics

Volumn 2, Issue 9, 2003, Pages 919-927

  Gatenby, Robert A ^a   Vincent, Thomas L ^a  

^a UNIVERSITY OF ARIZONA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MODEL; CELL TRANSFORMATION; EVOLUTION; GAME; GENETIC SELECTION; HUMAN; MATHEMATICS; NEOPLASM; PATHOLOGY; PHENOTYPE; POPULATION DYNAMICS; REVIEW;

CELL TRANSFORMATION, NEOPLASTIC; EVOLUTION; GAME THEORY; HUMANS; MATHEMATICS; MODELS, BIOLOGICAL; MODELS, GENETIC; NEOPLASMS; PHENOTYPE; POPULATION DYNAMICS; SELECTION (GENETICS);

EID: 0642349133     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Brown, J. M. and Giaccia, A. J. The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. Cancer Res., 58: 1408-1416, 1998. (Pubitemid 28193601)
2. Gatenby, R. A. and Maini, P. M. Mathematical oncology. Nature, 421: 321, 2003.
3. Alberts, B., Bray, D., Lewis, J., Raff, M., Roberts, K., and Watson, J. Molecular Biology of the Cell (3rd ed.), p. 1267. New York, NY: Garland Publishing, Inc., 1994.
4. Gatenby, R. A. and Gawlinski, E. T. A reaction-diffusion model of cancer invasion. Cancer Res., 56: 4740-4743, 1996.
5. Gatenby, R. A. Population ecology issues in tumor growth. Cancer Res., 51: 2541-2547, 1991.
6. Adam, J. A. and Bellomo, N. (eds.). A Survey of Models for Tumour-Immune System Dynamics. Boston, MA: Birkhauser, 1996.
7. Murray, J. D. Mathematical Biology (2nd ed.), pp. 80-81. Berlin: Springer, 1993.
8. Volterra, V. Variazionie fluttuazioni del numero d'individvi in specie animali conviventi. Mem. Acad. Lincei, 2: 21-113, 1926.
9. Lotka, A. J. Undamped oscillations derived from the law of mass action. J. Am. Chem. Soc., 42: 1595-1599, 1920.
10. Fearon, E. R. and Vogelstein, B. A. A genetic model for colorectal tumorigenesis. Cell, 61: 759-767, 1991.
11. Ilyas, M., Straub, J., Tomlinson, I. P. M., and Bdmer, W. F. Genetic pathways in colorectal and other cancers. Eur. J. Cancer, 35: 335-351, 1999. (Pubitemid 29151929)
12. Yasuda, S., Fujii, H., Nakahara, Y., Nishiumi, M., Takahashi, W., Ide, M., and Shohtsu, A. 18f-FDG PET detection of colonic adenomas. J. Nucl. Med., 42: 989-992, 2001. (Pubitemid 32595293)
13. Park, H. J., Lyons, J. C., Ohtsubo, T., and Song, C. W. Acidic environment causes apoptosis by increasing caspase activity. Br. J. Cancer, 80: 1892-1897, 1999. (Pubitemid 29391271)
14. Williams, A. C., Collard, T. J., and Paraskeva, C. An acidic environment leads to p53 dependent induction of apoptosis. Oncogene, 18: 3199-3204, 1999.
15. Rohzin, J., Sameni, M., Ziegler, G., and Sloane, B. F. Pericellular pH affects distribution and secretion of cathepsin B in malignant cells. Cancer Res., 54: 6517-6525, 1994.
16. Lardner, A. The effects of extracellular pH on immune function. Leuk. Biol., 69: 522-530, 2001. (Pubitemid 32294836)
17. Xu, L. and Fidler, I. J. Acidic pH-induced elevation in interleukin 8 expression by human ovarian carcinoma cells. Cancer Res., 60: 4610-4616, 2000. (Pubitemid 32103647)
18. Shi, Q., Le, X., Wang, B., Abbruzzese, J. L., Xiong, Q., He, Y., and Xie, K. Regulation of vascular endothelial growth factor expression by acidosis in human cancer cells. Oncogene, 20: 3751-3756, 2001. (Pubitemid 32624967)
19. von Mehren, M., Adams, G. P., and Weiner, L. M. Monoclonal antibody therapy for cancer. Annu. Rev. Med., 54: 334-369, 2003.
20. Riethmuller, G., Schneider-Gadicke, E., Schlimok, G., Schmiegelll, W., Raab, R., Hoffken, K., Gruber, R., Pichlmaier, H., Hirche, H., Pichlmayr, R., et al. Randomized trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma. German Cancer Aid 17-1A Study Group. Lancet, 343: 1177-1183, 1994. (Pubitemid 24147551)
21. Riethmuller, G., Holz, E., Schlimok, G., Schmiegel, W., Raab, R., Hofken, K., Gruber, R., Funke, I., Pichlmaier, H., Hirche, H., Buggisch, P., Witte, J., and Pichlmayr, R. Monoclonal antibody therapy for resected Dukes' C colorectal cancer: seven-year outcome of a multicenter randomized trial. J. Clin. Oncol., 16: 1788-1794, 1998.
22. Fan, Z., Baslega, J., Masui, H., and Mendelsohn, J. Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established A431 cell xenografts. Cancer Res., 53: 4637-4642, 1992.
23. Baselga, J., Norton, L., Masui, H., Pandiella, A., Coplan, K., Miller, W. H., Jr., and Mendelsohn, J. Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies. J. Natl. Cancer Inst., 85: 1327-1333, 1993. (Pubitemid 23249725)
24. Coldman, A. J. and Goldie, J. H. A model for the resistance of tumor cells to cancer chemotherapeutic agents. Math. Biosci., 65: 292-307, 1983.
25. Vincent, T. L., Cohen, Y., and Brown, J. S. Evolution via strategy dynamics. Theor. Popul. Biol., 44: 149-176, 1993.
26. Vincent, T. L. Strategy dynamics and the ESS. In: Dynamics of Complex Interconnected Biological Systems, Mathematical Modeling, pp. 236-249. Boston, MA: Birkhäuser, 1990.
27. Vincent, T. L. and Brown, J. S. An evolutionary response to harvesting. In: Modeling and Management of Resources under Uncertainty, Lecture Notes in Biomathematics, pp. 83-99. Heidelberg: Springer-Verlag, 1987.
28. Case, T. J. Coevolution in resource-limited competition communities. Theor. Popul. Biol., 21: 69-91, 1982.
29. Rummel, J. D. and Roughgarden, J. Some differences between invasion-structured and coevolution structured competitive communities: a preliminary theoretical analysis. Oikos, 41: 477-486, 1983. (Pubitemid 15276616)
30. Rummel, J. D. and Roughgarden, J. A theory of faunal buildup for competition communities. Evolution, 39: 1009-1033, 1985. (Pubitemid 17248513)
31. Brown, J. S. and Vincent, T. L. Coevolution as an evolutionary game. Evolution, 41: 66-79, 1987.
32. Hines, W. G. S. Evolutionary stable strategies: a review of basic theory. Theor. Popul. Biol., 31: 195-272, 1987.
33. Vincent, T. L. and Brown, J. S. Stability in an evolutionary game. Theor. Popul. Biol., 26: 408-427, 1984.
34. Vincent, T. L. An evolutionary game theory for differential equation models with reference to ecosystem management. In: T. Basar and A. Haurie (eds.), Advances in Dynamic Games and Applications, pp. 356-374. Boston, MA: Birkhauser, 1994.
35. Ichihashi, M. and Kitajima, Y. Chemotherapy induces or increases expression of multi-drug resistance-associated protein in malignant melanoma cells. Br. J. Dermatol., 144: 745-750, 2001. (Pubitemid 32374776)
36. Matsumoto, Y., Takano, H., and Fojo, T. Cellular adaptation to drug exposure: evolution of the drug-resistant phenotype. Cancer Res., 57: 5086-5092, 1997. (Pubitemid 27498124)
37. Ciardiello, F., Bianco, R., Damiano, V., De Lorennnzo, S., Pepe, S., De Placido, S., Fan, Z., Mendelsohn, J., Bianco, A. R., and Tortora, G. Antitumor activity of sequential treatment with topotecan and antiepidermal growth factor receptor monoclonal antibody C225. Clin. Cancer Res., 5: 509-516, 1999.
38. Petit, A., Rak, J., Hung, M., Rockwell, P., Goldstein, N., Fendly, B., and Kerbel, R. S. Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implication for signal transduction therapy of solid tumors. Am. J. Pathol., 151: 1523-1530, 1997. (Pubitemid 27527914)
39. Cobleigh, M., Vogel, C., Tripathy, D., Robert, N. J., Scholl, S., Fehrenbacher, L., Wolter, J. M., Paton, V., Shak, S., Lieberman, G., and Slamon, D. J. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-ovrexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J. Clin. Oncol., 17: 2639-2648, 1999. (Pubitemid 29415219)
40. Slamon, D., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., Baselga, J., and Norton, L. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic disease that overexpresses HER2. N. Engl. J. Med., 344: 783-792, 2001. (Pubitemid 32222155)
41. Norton, L., Slamon, D., and Leyland-Jones, B. Overall survival (OS) advantage to simultaneous chemotherapy (CRx) plus the humanized anit-HER2 monoclonal antibody Herceptin (H) in HER2-over-expressing (HER2+) metastatic breast cancer (MBC) (Abstract). Proc. Am. Soc. Clin. Oncol., 18: A127, 1999.
42. Baselga, J. Clinical trials of Herceptin (trastuzuman). Eur. J. Cancer, 37: S18-S24, 2001.